Treatment-refractory bipolar disorder: classification to aid in clinical management

Bibliography

• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorder in the national comorbidity survey replication. Arch Gen Psychiat 2005;62:617-27
   PubMed Web of Science ®Google Scholar
• Calabrese JR. Overview of patient care issues and treatment in bipolar spectrum and bipolar II disorder. J Clin Psychiat 2008;69(6):e18
   PubMedGoogle Scholar
• Perlis RH, Miyahara S, Marangell LB, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systemic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiat 2004;55(9):875-81
   PubMed Web of Science ®Google Scholar
• Schneck CD, Milkowitz DJ, Miyahara S, et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiat 2008;165(3):370-7
   PubMed Web of Science ®Google Scholar
• Gajwani P, Kemp DE, Muzina D, et al. Acute treatment of mania: an update on new medications. Curr Psychiatry Rep 2006;8:504-9
   PubMedGoogle Scholar
• Gao K, Gajwani P, Elhaj O, et al. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiat 2005;66:1376-85
   PubMed Web of Science ®Google Scholar
• Ketter TA, Wang PW, Nowasky C, et al. Advances in treatment of bipolar disorder. In: Ketter TA, editor, Treatment of acute mania in bipolar disorder. American Psychiatric Publishing, Inc. Chapter 2, p. 18-27
   Google Scholar
• Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systemic review of randomized, controlled trials. Am J Psychiat 2004;161(9):1537-47
   PubMed Web of Science ®Google Scholar
• Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356(17):1711-22
   PubMed Web of Science ®Google Scholar
• Colom F, Vieta E, Marti'nez-Ara'n A, et al. Clinical factors associated with treatment noncompliance in the euthymic bipolar patients. J Clin Psychiat 2000;61(8):549-55
   PubMedGoogle Scholar
• Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52(6):805-11
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003;64(2):161-74
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arc Gen Psychiatry 2007;64(5):543-52
   PubMed Web of Science ®Google Scholar
• Altman S, Haeri S, Cohen LJ, et al. Predictors of relapse in bipolar disorder: A review. J Psychiatr Pract 2006;12(5):269-82
   PubMedGoogle Scholar
• Judd LL, Schettler PJ, Akiskal HS, et al. Residual symptom recovery from major affective episodes in bipolar disorder and rapid episode relapse/recurrence. Arch Gen Psychiatry 2008;65(4):386-94
   PubMed Web of Science ®Google Scholar
• Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity and tolerance phenomena. Neurosci Biobehav Rev 2007;31(6):858-73
   PubMed Web of Science ®Google Scholar
• Frye M, Guochuan ET, Teresa H, et al. Low Cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry 2007;61:162-6
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systemic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008;11(7):999-1029
   PubMedGoogle Scholar
• Hirschfield RMA, Bowden CL, Keck PE, et al. Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J psychiatry (supplement) 2002;159(4):1-50
   Google Scholar
• Keck PE, Perlis RH, Otto MW, et al. Treatment of bipolar disorder 2004. Post Grad Med Spec Rep 2004;1:1-120
   Google Scholar
• Tohen M, Chengappa KNR, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-9
   PubMed Web of Science ®Google Scholar
• Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004;24:599-606
   PubMed Web of Science ®Google Scholar
• Sachs G, Chengappa KNR, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6:213-23
   PubMed Web of Science ®Google Scholar
• Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146-54
   PubMed Web of Science ®Google Scholar
• Yatham LN, Grossman F, Augustyns I, et al. Mood stabilizers plus risperidone or placebo in treatment of acute mania: international, double-blind, placebo-controlled trial. Br J Psychiatry 2003;182:141-7
   PubMed Web of Science ®Google Scholar
• Chou JC, Czobor P, Charles O, et al. Acte mania: haloperidol dose and augmentation with lithium or lorazepam. J Clin Psychophramacol 1999;19(6):500-5
   PubMed Web of Science ®Google Scholar
• Lenox RH, Newhouse PA, Creelman WL, et al. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatry 1992;53(2):47-52
   PubMed Web of Science ®Google Scholar
• Small JG, Klapper MH, Marhenke JD, et al. Lithium combined with carbamazepine and haloperidol in the treatnment of mania. Psychopharmacol Bull 1995;31(2):265-72
   PubMed Web of Science ®Google Scholar
• Pratoomsri W, Yatham LN, Sohn C-H, et al. Oxcarbazepine add-on in the treatment of refractory bipolar disorder. Bipolar Disord 2005;7(suppl 5):37-42
   PubMed Web of Science ®Google Scholar
• Majczenko TG, Stewart JT. Oxcarbazepine treatment of refractory bipolar disorder. South Med J 2007;100(4):415 [abstract]
   PubMedGoogle Scholar
• Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute mania episodes: a review of 50 years' experience. Am J Psychiatry 1994;151(2):169-76
   PubMed Web of Science ®Google Scholar
• Nascimento AL, Appolinario C, Segenreich D, et al. Maintenance electroconvulsive therapy for recurrent refractory mania. Bipolar Disord 2006;8:301-3
   PubMed Web of Science ®Google Scholar
• Tsao CI, Jain S, Gibson RH, et al. Maintenance ECT for recurrent medication-refractory mania. J ECT 2004;20(2):118-9
   PubMed Web of Science ®Google Scholar
• Green AI, Tohen M, Patel JK, et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000;157(6):982-6
   PubMed Web of Science ®Google Scholar
• Cluver JS, Hardesty SJ. Propofol for severe, refractory mania: a case report. J Clin Psychiatry 2006;67(1):165-6
   PubMedGoogle Scholar
• Judd LL, Akiskal AH, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7
   PubMed Web of Science ®Google Scholar
• Tondo L, Icacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risks and prevention. CNS Drugs 2003;17:491-511
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Post RM, Black DO, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of large, multisite study. J Clin Psychiatry 2006;67:1551-60
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnosis of bipolar disorder. Psychiatr Serv 2007;58(1):85-91
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Wingo AP, Filkowski MA, et al. long-term antidepressant treatment of bipolar disorder: meta-analysis of benefits and risks. Acta Psychiatr Scand 2008;118(5):347-56
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006;8(5 Pt 2):625-39
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind placebo-controlled clinical trials. Bipolar Disord 2008;10:323-33
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese JR, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of Quetiapine in the treatment of bipolar I or II depression. Am J psychiatry 2005;162:1351-60
   PubMed Web of Science ®Google Scholar
• Thase ME, Macfadden W, Wisler RH, et al. Efficacy of Quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II study). J clin Pyschophamacol 2006;26:600-9
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol and risperidone. Am J Psychiatry 2006;163:210-6
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Ko JY, Katzow JJ, et al. Oxcarbazepine treatment of refractory bipolar disorder: a retrospective chart review. Bipolar Disord 2002;4:70-4
   PubMed Web of Science ®Google Scholar
• van der Loos M, Nolen WA, Vieta E. Lamotrigine as add-on to lithium in bipolar depresión [abstract P268]. Bipolar Disord 2007;9(Suppl):107
   Google Scholar
• Nolen WA, Kupka RW, Hellemann G, et al. Tranylcypromine vs. Lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand 2007;115:360-5
   PubMed Web of Science ®Google Scholar
• Vaidya NA, Mahableshwarkar AR, Shahid R. Continuation and maintenance ECT in treatment-resistant bipolar disorder. J ECT 2003;19(1):10-6
   PubMed Web of Science ®Google Scholar
• Sikdar S, Kulhara P, Avasthi A, et al. Combined chlorpromazine and electroconvulsive therapy in mania. Br J Psychiatry 1994;164(6):806-10
   PubMedGoogle Scholar
• Nierenberg AA, Alpert JE, Gardner-Schuster EE, et al. Vagus nerve stimulator: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry 2008;64(6):455-60
   PubMed Web of Science ®Google Scholar
• Marangell LB, Suppes T, Zboyan HA, et al. A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder. J Clin Psychiatry 2008;69(2):183-9
   PubMedGoogle Scholar
• Baldessarini R, Henk H, Sklar A, et al. Psychotropic medications for patients with bipolar disorder in the United states: polytherapy and adherence. Psychiatr Serv 2008;50(10):1175-83
   Google Scholar
• Siegffried K, Calabrese JR, Johnson G, et al. International consensus group on the evidence-based pharmacologic treatment of bipolar I and II depression. J Clin Psychiatry 2008;69:1632-46
   PubMedGoogle Scholar
• Kessing LV, Andersen PK. Does the risk of developing dementia increases with the number of episodes in patients with depressive disorder and in patients with bipolar disorder?. J Neurol Neurosurg Psychiatry 2004;75(12):1662-6
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Vieta E, El Mallakh R, et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 2004;56:957-63
   PubMed Web of Science ®Google Scholar